
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
Learn more about Invea and the team that is making a difference.
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
– Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology
– Company also primed to advance additional programs, including a pan-inflammasome inhibitor
Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode the gut-brain axis, innate immunity, and neuroinflammation for target identification and drug discovery
© 2023 Invea Therapeutics, Inc. All rights reserved | Privacy Policy | Disclaimer